Top Page
OncoSil Medical Ltd
(Sydney:OSL)
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
OncoSil Medical Ltd Business Overview & Revenue Model
OncoSil Medical Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.41M | 516.63K | 367.68K | 231.79K | 213.07K | 2.76M | Gross Profit |
| -2.42M | -993.12K | -6.49M | -6.73M | -6.23M | 2.61M | EBIT |
| -13.09M | -11.98M | -12.55M | -11.41M | -11.63M | -7.21M | EBITDA |
| -13.06M | -11.98M | -11.32M | -11.41M | -10.51M | -6.87M | Net Income Common Stockholders |
| -13.07M | -11.91M | -11.34M | -10.73M | -10.43M | -4.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 13.04M | 4.50M | 9.39M | 11.28M | 12.24M | 21.00M | Total Assets |
| 15.29M | 6.72M | 11.47M | 13.07M | 14.15M | 24.06M | Total Debt |
| 60.45K | 70.67K | 170.81K | 304.21K | 484.37K | 109.94K | Net Debt |
| -12.98M | -4.43M | -9.22M | -10.98M | -11.76M | -20.89M | Total Liabilities |
| 1.79M | 1.98M | 1.59M | 1.91M | 2.45M | 2.16M | Stockholders Equity |
| 13.51M | 4.74M | 9.88M | 11.16M | 11.70M | 21.90M |
| Cash Flow | Free Cash Flow | ||||
| -12.84M | -11.02M | -11.37M | -10.12M | -8.87M | -4.48M | Operating Cash Flow |
| -12.63M | -10.82M | -11.32M | -10.11M | -8.82M | -4.46M | Investing Cash Flow |
| -208.41K | -197.06K | -57.82K | -5.83K | -54.00K | -20.72K | Financing Cash Flow |
| 16.40M | 6.13M | 9.49M | 9.16M | 111.25K | 17.79M |
OncoSil Medical Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
35 Underperform | AU$11.29M | ― | -199.38% | ― | 271.05% | 42.55% | |
| $2.16M | ― | -119.28% | ― | ― | ― | ||
| $77.69M | ― | -99.05% | ― | ― | ― | ||
54 Neutral | AU$205.88M | ― | -37.20% | ― | ― | 32.02% | |
53 Neutral | AU$702.83M | ― | -112.97% | ― | ― | -84.82% |
OncoSil Medical Ltd Corporate Events
OncoSil Medical Ltd has announced an Extraordinary General Meeting (EGM) scheduled for July 8, 2025, in Melbourne. This meeting is crucial for shareholders as it impacts their holdings, and they are encouraged to vote either in person or by proxy. The meeting will address significant business matters, and shareholders are advised to seek professional guidance if unsure about their voting decisions. This EGM could have implications for the company’s strategic direction and stakeholder interests.
OncoSil Medical Limited has completed a capital consolidation on a 1 for 400 basis, as approved by shareholders, to streamline its capital structure. This move is part of the company’s strategy to enhance its market position as it continues to commercialize its innovative cancer treatment technology. The consolidation is expected to impact trading, with normal trading on a post-consolidation basis set to commence on June 13, 2025.
OncoSil Medical Ltd has announced the opening of a Security Purchase Plan (SPP) for eligible shareholders, primarily in Australia and New Zealand. This plan allows shareholders to purchase up to $100,000 of new fully paid OncoSil ordinary shares without incurring brokerage or transaction costs. The offer includes one free attaching option for every new share issued, with the options having an exercise price of $0.003 each and an expiry date of July 31, 2027. The SPP aims to strengthen OncoSil’s financial position as it continues to commercialize its innovative cancer treatment technology.
OncoSil Medical Ltd has announced the issuance of over 1 billion ordinary shares without disclosure under the Corporations Act, in compliance with relevant legal provisions. This move reflects the company’s strategic financial maneuvers to potentially enhance its capital structure, which could influence its market position and stakeholder interests.
OncoSil Medical Ltd has announced a consolidation of its securities, which was approved by shareholders at an Extraordinary General Meeting on May 29, 2025. This reorganization affects various securities, including ordinary shares and options with different expiration dates, and is part of the company’s strategic efforts to streamline its capital structure and potentially enhance shareholder value.
OncoSil Medical Ltd announced that all resolutions at their Extraordinary General Meeting were carried by poll. This includes the approval of share consolidation, future issue of shares, an omnibus plan, and the issuance and ratification of options. The successful passing of these resolutions is expected to impact the company’s operational strategies and potentially enhance its market position, benefiting stakeholders by aligning with its growth objectives.
OncoSil Medical Ltd has announced a proposed issue of securities under a securities purchase plan, aiming to issue a total of 666,666,667 new securities. This move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing its capital base, which may be used for further development and expansion activities.
OncoSil Medical Ltd has announced a proposed issuance of securities, including options and ordinary shares, set to take place on July 11, 2025. This move is part of a strategic effort to raise capital, potentially enhancing the company’s financial position and supporting its ongoing operations and growth initiatives within the oncology sector.
OncoSil Medical Ltd has released a presentation regarding a capital raise, emphasizing that the information provided is not an offer for securities but rather a general overview of the company’s operations and future prospects. The presentation includes forward-looking statements about the company’s product candidates and their potential regulatory approvals, highlighting the risks and uncertainties involved. Stakeholders are advised to seek independent advice due to the speculative nature of the information presented.
OncoSil Medical Ltd has announced a Share Purchase Plan and Placement to raise approximately $8.7 million before offer costs, subject to shareholder approval. The capital raising initiative includes offering new shares and options to eligible shareholders and invited investors, with Bell Potter appointed as the Lead Manager. This move is expected to bolster the company’s financial position and support its ongoing operations and strategic initiatives in the medical device industry.
OncoSil Medical Ltd has announced an $8.7 million capital raise to accelerate the commercialization of its pancreatic cancer treatment device. The funds will support ongoing clinical trials and commercialization efforts, with a focus on expanding market access in Europe and existing jurisdictions. The capital raise includes a placement and a Share Purchase Plan (SPP), with strong backing from institutional investors, including Pengana High Conviction Equities Fund. The completion of two major clinical trials, PANCOsil and TRIPP-FFX, is expected to significantly enhance the company’s market access and operational cash flow by the second half of 2026.
OncoSil Medical Ltd has requested a trading halt on its securities pending an announcement related to a capital raise. This move indicates a potential strategic financial maneuver that could impact the company’s operations and market positioning, with implications for investors and stakeholders as they await further details.
OncoSil Medical Limited announced the results of a comparative analysis demonstrating the superiority of its OncoSil™ device over Stereotactic Body Radiation Therapy (SBRT) in treating locally advanced pancreatic cancer. The study showed that OncoSil™ significantly extends overall survival and progression-free survival compared to SBRT, with a higher rate of downstaging and surgical resection. These findings, presented at the Digestive Disease Week 2025, highlight the potential of OncoSil™ in treating earlier stages of pancreatic cancer and reinforce its efficacy and safety when added to standard chemotherapy. This development marks a significant milestone for OncoSil Medical, enhancing its positioning in the cancer treatment industry.
OncoSil Medical Ltd has announced the quotation of 2,076 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 5, 2025. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase liquidity, reflecting its ongoing commitment to growth and value creation for its stakeholders.
OncoSil Medical Ltd reported record quarterly dose sales for Q3 FY25, driven by increased clinical adoption of the OncoSil™ device. The company saw a 233% increase in dose sales compared to the previous year, contributing to an 83% rise in year-to-date sales and a 135% increase in year-to-date revenues. This growth highlights the company’s successful market penetration and strategic advancements, including receiving MDR approval and expanding its presence in German hospitals. The financial results indicate a promising outlook for future revenue growth as sales figures are expected to be more fully realized in upcoming quarters.
OncoSil Medical Ltd has announced an update to its previous notification regarding the consolidation or split of its securities, specifically including the OSLOC option expiring on December 20, 2027. This update signifies a strategic move in managing its financial instruments, potentially impacting stakeholders by altering the structure of investment opportunities within the company.
OncoSil Medical Ltd has announced a security consolidation, affecting various securities including ordinary shares and options with different expiration dates. This reorganization is set to commence trading on a deferred settlement basis from June 3, 2025, with a record date of June 4, 2025, and an issue date of June 12, 2025. The consolidation is part of the company’s strategic efforts to streamline its securities structure, which could impact its market positioning and provide clarity for stakeholders.
OncoSil Medical Limited has announced that the Federal Joint Committee in Germany has initiated a tender process to select a Contract Research Organisation for a study on the OncoSil™ device. This study will evaluate the device’s effectiveness in combination with chemotherapy for treating unresectable, locally advanced pancreatic cancer. This development is a significant step towards potential inclusion in German treatment guidelines and the statutory health insurance system, which could impact the company’s market positioning and stakeholder interests.
OncoSil Medical Ltd has announced an Extraordinary General Meeting (EGM) scheduled for May 29, 2025, in Carlton, Victoria. This meeting is significant for shareholders as it will address matters affecting their shareholding, and they are encouraged to participate either in person or by proxy. The announcement underscores the importance of shareholder involvement in the company’s decision-making processes, potentially impacting its strategic direction and market positioning.
OncoSil Medical Ltd reported record quarterly dose sales in Q3 FY25, reflecting a 233% increase compared to the previous year, driven by the growing clinical adoption of the OncoSil™ device. The company also received a $1.05 million R&D tax incentive and made strategic appointments and advancements, including the addition of Ms. Lel Smits to the Board of Directors and Ms. Shelley Steyn as CFO. Advisory Board meetings in the UK and Germany outlined strategic pathways for the device’s advancement, aiming to strengthen OncoSil’s position in the healthcare systems of these regions.
OncoSil Medical Limited has appointed Nathan Jong as the new Company Secretary, succeeding Christian Dal Cin. Nathan Jong, with his extensive experience in corporate secretarial and finance roles within the life sciences sector, will handle communication with the ASX regarding listing rule matters. This appointment is expected to strengthen OncoSil’s operational framework as it continues to commercialize its innovative pancreatic cancer treatment device globally.
OncoSil Medical Limited has appointed Ms. Shelley Steyn as Chief Financial Officer, effective May 5, 2025, as part of its strategy to strengthen leadership during a critical development phase. Ms. Steyn’s extensive experience in financial roles is expected to enhance OncoSil’s strategic priorities, improve financial control, and support the company’s efforts in closing clinical trial recruitments and resubmitting a marketing authorization application to the Therapeutics Goods Association.